Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

Bayer’s Kerendia Gets FDA Priority Review for Heart Failure with Preserved Ejection Fraction

Fineline Cube Mar 18, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that a supplementary New Drug Application (sNDA) for...

Policy / Regulatory

HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process

Fineline Cube Mar 18, 2025

HMZS Biopharmaceutical, a Chinese company that won a bid for its phloroglucinol in the 10th...

Company Medical Device

IceCure Medical Secures Chinese Patent for Cryogenic System Connector

Fineline Cube Mar 18, 2025

Israel-based IceCure Medical Ltd. (NASDAQ: ICCM) announced receiving patent authorization from the China National Intellectual...

Company

FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development

Fineline Cube Mar 18, 2025

US-based biotech FibroGen Inc. (NASDAQ: FGEN) released its Q4 and full-year 2024 financial results, showing...

Company Deals

Taiho Pharmaceutical to Acquire Araris Biotech for USD 400 Million, Expanding ADC Portfolio

Fineline Cube Mar 18, 2025

Japan-based Taiho Pharmaceutical Co., Ltd. announced plans to fully acquire Araris Biotech AG, a Swiss...

Company Drug

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401

Fineline Cube Mar 18, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) announced receiving clinical trial approval for its investigational...

Company Medical Device

Lifetech Scientific’s Aortic Stent System Approved by China’s NMPA

Fineline Cube Mar 18, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced receiving market approval from the National Medical Products...

Company Deals

PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services

Fineline Cube Mar 18, 2025

Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed...

Company Drug

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia

Fineline Cube Mar 18, 2025

Shanghai-based Rona Therapeutics Inc. announced receiving approval from the US Food and Drug Administration (FDA)...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis

Fineline Cube Mar 18, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clearance from the National Medical...

Company Drug

Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer

Fineline Cube Mar 18, 2025

China-based Alphamab Oncology (HKG: 9966) announced receiving Breakthrough Therapy Designation (BTD) from the National Medical...

Company Deals

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio

Fineline Cube Mar 17, 2025

On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN)....

Company Deals

AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies

Fineline Cube Mar 17, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...

Company Drug

Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan

Fineline Cube Mar 17, 2025

US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...

Company Drug

Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment

Fineline Cube Mar 17, 2025

Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in...

Company Medical Device

ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval

Fineline Cube Mar 17, 2025

China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control...

Company Deals Drug

Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific

Fineline Cube Mar 17, 2025

Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer...

Company

Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy

Fineline Cube Mar 17, 2025

California-based Phenomenex, a leading manufacturer of chromatography consumables, announced the inauguration of its R&D center...

Company Drug

BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma

Fineline Cube Mar 17, 2025

US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...

Company Deals

Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline

Fineline Cube Mar 17, 2025

Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...

Posts pagination

1 … 238 239 240 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.